GENETIC POLIMORPHISMS OF ENZYMES INVOLVED IN FOLATE METABOLISM IN HEALTHY SLOVENIAN POPULATION
Abstract
Background. Enzymes that play a major role in folate metabolism are 5,10-methylenetetrahydrofolate reductase (MTHFR), thymidilate synthase (TS), methionine synthase (MS) and methionine synthase reductase (MTRR). Polymorphisms in their corresponding genes alter their enzymatic activity. The aim of this study was to determine the frequencies of polymorphic MTHFR and TS genotypes in healthy adults from Slovenian population in order to estimate the proportion of individuals that may be at risk for certain diseases or increased toxicity if treated with antifolate drugs.
Methods. MTHFR and TS polymorphisms were studied by a genotyping technique, based on polymerase chain reaction (PCR) followed by restriction enzyme analysis. DNA samples from 122 unrelated adult healthy subjects were obtained from the Tissue Typing Center and University Children’s Hospital in Ljubljana.
Results. In the analyzed group 62.3% of individuals carried at least one polymorphic MTHFR 677T allele and 52.5% carried at least one polymorphic 1298C allele. Only 12% of individuals had no polymorphic MTHFR allele. The frequencies of MTHFR genotypes were influenced by the age of the subjects under investigation. The frequency of the TS 3R/3R genotype in Slovenian population was significantly lower than in some other populations.
Conclusions. Genetic polymorphisms in folate metabolic pathway occur with high frequency in Slovenian population and modify cancer risk. Regarding the influence of these polymorphisms on the efficacy of treatment with antifolate drugs the introduced genotyping method could contribute to the individualization of treatment with methotrexate and 5-fluorouracil.
Downloads
References
Matthews RG et al. Folates and pterins. In: Blakley RL, Benkovik SJ eds. Chemistry and biochemistry of folates. New York: Wiley Interscience, 1984: 497–553.
Marks DB, Marks AD, Smith CM. Basic medical biochemistry. Lippincot Williams & Wilkins, 1996: 613–22.
Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular desise: a common mutation in metylenetetrahidrofolate reductase. Net Genet 1995; 10: 111–3.
Weisberg I, Tran P, Christensen B et al. A second genetic polymorphism in metylenetetrahidrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169–72.
Rady PL, Szucs S, Grady J et al. Genetic polymorphisms of metylenetetrahidrofolate reductase (MTHFR) and metionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 2002; 107: 162–8.
Van der Put NM, Gabreels F, Stevens EM et al. A second common mutation in the metylenetetrahidrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044–51.
Horie N, Aiba H, Oguro K et al. Functional analysis and DNA polymorphism of the tamdemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191–7.
Hishida A, Matsuo K, Hamajima N et al. Associations between polymorphisms in the thymidylate sinthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Hematologica 2003; 88: 159–66.
Jacques PF, Bostom AG, Selhub J et al. Effects of polymorphisms of metionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI family heart study. Atherosclerosis 2003; 166: 49–55.
Ludwig ML, Matthews RG. Structure-based perspectives on B12-dependent enzymes. Annu Rev Biochem 1997; 66: 269–313.
Gaughan DJ, Kluijtmans LAJ, Barbaux S et al. The methionine synthase reductase A66G polymorphism is a novel genetic determinant of plasma homocysteine concentration. Atherosclerosis 2001; 157: 451–66.
Rosenblatt DS, Fenton WA. Inherited disorders of folate and cobalamintransport and metabolism. In: Scriver CR ed. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001: 3897–933.
Skibola CF, Smith MT, Kane E et al. Polymorphisms in the metylenetetrahidrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999; 96: 13217–20.
Chen J, Giovannucci EL, Hunter DJ et al. MTHFR polymorphism, methylreplete diets and the risk of colorectal carcinoma and adenoma among U.S. men and women: an example for gene-environment interactions in colorectal tumorigenesis. J Nutr 1999; 129: 560S–4S.
Dolžan V, Ravnik-Glavač M, Golouh R, Breskvar K. Methylene tetrahidrofolate reductase polymorphism and susceptibility to colorectal cancer. In: Javornik B, Lutar Z eds. Genetika 2003. Proceedings of 3rd congress of the genetic society of Slovenia with international participation. Ljubljana: Genetic society of Slovenia, 2003: 153–4.
Shen H, Xu Y, Zheng Y et al. Polymorphisms of 5, 10-metylenetetrahidrofolate reductase and risk of gastric cancer in a Chinese population: a casecontrol study. Int J Cancer 2001; 95: 332–6.
Song C, Xing D, Tan W et al. Metylenetetrahidrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 2001; 61: 3272–5.
Skibola CF, Smith MT, Hubbard A et al. Polymorphisms in the thymidylate sinthase and serine hydroxymethyltransferase genes and risk of adult acute leukemia. Blood 2002; 99: 3786–91.
Salonga D, Danenberg KD, Johnson M et al. Colorectal tumors responding to 5-flourouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate sinthase and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322–7.
Refsum H, Ueland PM, Nygard O et al. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31–62.
Mills JL, McPartlin JM, Kirke PN et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995; 345: 149–51.
Van Rooij IALM, Vermeij-Keers C, Kluijtmans LAJ et al. Does the interaction between maternal folate intake and the metylenetetrahydrofolate reductase polymorphisms affect the risk of cleft lip with or withouth cleft palate. Am J Epidemiol 2003; 157: 583–91.
van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350: 2033–41.
Bathum L, Von Bornemann Hjelmborg J, Christiansen L, Madsen JS, Skytthe A, Christensen K. Evidence for an association of methylene tetrahydrofolate reductase polymorphism C677T and an increased risk of fractures: results from a population-based Danish twin study. Osteoporos Int 2004; 15: 659–64 [Epub ahead of print].
Evans WE, McLeod HL. Pharmacogenomics – drugs disposition, drug targets and side effects. N Engl J Med 2003; 348: 538–49.
Chiusolo P, Reddiconto G, Casorelli I et al. Preponderance of metylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002; 13: 1915–8.
Krajinovic M, Costea I, Chiasson S. Polymorphism of TS gene and outcome of acute lymphoblastic leukemia. Lancet 2002; 359: 1033–4.
Urano W, Taniguchi A, Yamanaka H et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12: 183–90.
Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003; 11: 593–600.
Iacopetta B, Grieu F, Joseph D et al. A polymorphism in the enhancher region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-flourouracil. Brit J Cancer 2001; 85: 827–30.
Yi P, Pogribny IP, James SJ. Multiplex PCR for simultaneous detection of 667C- > T and 1298A- > C polymorphisms in methylenetetrahydrofolate reductase gene for population studies of cancer risk. Cancer Letters 2002; 181: 209–13.
Bohanec P. Vpliv genskih polimorfizmov v presnovni poti folata na tveganje za akutno limfatično levkemijo pri otrocih. Diplomsko delo. Ljubljana: Fakulteta za kemijo in kemijsko tehnologijo, 2004: 39–54.
Meglič L, Stegnar M, Milanez T et al. Factor V Leiden, prothrombin 2010G → A, methylenetetrahydrofolate reductase 677C → T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous tromboembolism. Eur J Obstet Gynecol Reprod Biol 2003; 111: 157– 63.
Krajinovic M, Lemiex-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. The Pharmacogenomics Journal 2004; 4: 66–72.
Franco RF, Simoes BP, Tone LG, Gabellini SM, Zago MA, Falcao RP.The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br J Haematol 2001; 115: 616–8.
Wiemels JL, Smith RN, Taylor GM et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA 2001; 98: 4004–9.
Marsh S, Collie-Duguid ESR, Li T et al. Ethnic variation in thymidylate synthase enhancher region polymorphism among Caucasian and Asian populations. Genomics 1999; 58: 310–2.
Isotalo PA, Wells GA, Donnelly JG. Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. Am J Hum Genet 2000; 67: 986–90.
Tršan T. Analiza polimorfizma gena za metionin sintazo in vpliva na tveganje za nastanek raka debelega črevesa pri Slovencih. Diplomsko delo. Ljubljana: Biotehniška fakulteta, 2004: 30–39.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
